Literature DB >> 17130278

Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation.

Jose María Morales1, Beatriz Domínguez-Gil.   

Abstract

Cardiovascular risk factors after kidney transplantation are enhanced as a result of the chronic use of immunosuppressants. Tacrolimus with mycophenolate mofetil has become the most commonly used combination after kidney transplantation. Cardiovascular risk factors that are related to the use of this combined therapy have been analyzed in various clinical trials in comparison with other immunosuppressive therapies. This review summarizes the main results of these studies regarding arterial hypertension, lipid profile, posttransplantation diabetes, renal function, and even acute rejection rate. The aim is to characterize the cardiovascular risk profile of tacrolimus and mycophenolate mofetil association when compared with older and newer immunosuppressive associations.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17130278     DOI： 10.1681/ASN.2006080930

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


  10 in total

1.  Protein kinase CbetaII-mediated phosphorylation of endothelial nitric oxide synthase threonine 495 mediates the endothelial dysfunction induced by FK506 (tacrolimus).

Authors:  Valorie L Chiasson; Matthew A Quinn; Kristina J Young; Brett M Mitchell
Journal:  J Pharmacol Exp Ther       Date:  2011-03-07       Impact factor: 4.030

Review 2.  Assessment and management of hypertension in transplant patients.

Authors:  Matthew R Weir; Ellen D Burgess; James E Cooper; Andrew Z Fenves; David Goldsmith; Dianne McKay; Anita Mehrotra; Mark M Mitsnefes; Domenic A Sica; Sandra J Taler
Journal:  J Am Soc Nephrol       Date:  2015-02-04       Impact factor: 10.121

3.  Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect.

Authors:  Leslie G Cook; Valorie L Chiasson; Cheng Long; Gang-Yi Wu; Brett M Mitchell
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

4.  Beneficial effects of mycophenolate mofetil on cardiotoxicity induced by tacrolimus in wistar rats.

Authors:  Hanen Ferjani; Rim Timoumi; Ines Amara; Salwa Abid; Abedellatif Achour; Hassen Bacha; Imen Boussema-Ayed
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-24

5.  Nebivolol Effects on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients.

Authors:  Alfonso H Santos; Michael J Casey; Charles M Bucci; Shehzad Rehman; Mark S Segal
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-12-22       Impact factor: 3.738

Review 6.  Role of hypertension in kidney transplant recipients.

Authors:  Charalampos Loutradis; Pantelis Sarafidis; Smaragdi Marinaki; Miriam Berry; Richard Borrows; Adnan Sharif; Charles J Ferro
Journal:  J Hum Hypertens       Date:  2021-05-04       Impact factor: 3.012

7.  Cardiovascular diseases after kidney transplantation in Korea.

Authors:  Jong Cheol Jeong; Han Ro; Young-Hwan Hwang; Han Kyu Lee; Jongwon Ha; Curie Ahn; Jaeseok Yang
Journal:  J Korean Med Sci       Date:  2010-10-26       Impact factor: 2.153

8.  Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling.

Authors:  Kenichi Ishizawa; Qin Wang; Jinping Li; Osamu Yamazaki; Yoshifuru Tamura; Yoshihide Fujigaki; Shunya Uchida; Richard P Lifton; Shigeru Shibata
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

Review 9.  Hypertension in kidney transplant recipients.

Authors:  Maria-Eleni Alexandrou; Charles J Ferro; Ioannis Boletis; Aikaterini Papagianni; Pantelis Sarafidis
Journal:  World J Transplant       Date:  2022-08-18

10.  Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study.

Authors:  Jose Maria Morales; Roberto Marcén; Domingo del Castillo; Amado Andres; Miguel Gonzalez-Molina; Federico Oppenheimer; Daniel Serón; Salvador Gil-Vernet; Ildefonso Lampreave; Francisco Javier Gainza; Francisco Valdés; Mercedes Cabello; Fernando Anaya; Fernando Escuin; Manuel Arias; Luis Pallardó; Jesus Bustamante
Journal:  Nephrol Dial Transplant       Date:  2012-12       Impact factor: 5.992
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.